Evidence map›Paper›PMID 38353536›Full record

ArticleJournal of virology2024

A rapid and versatile reverse genetics approach for generating recombinant positive-strand RNA viruses that use IRES-mediated translation.

Tomokazu Tamura, Hirotaka Yamamoto, Saho Ogino, Yuhei Morioka, Shuhei Tsujino, Rigel Suzuki, Takahiro Hiono, Saori Suzuki, Norikazu Isoda, Yoshihiro Sakoda and 1 more

Abstract read
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tomokazu TamuraDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0003-1395-6610
Hirotaka YamamotoDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Saho OginoLaboratory of Microbiology, Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
Yuhei MoriokaDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Shuhei TsujinoDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Rigel SuzukiDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Takahiro HionoInstitute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.
Saori SuzukiDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Norikazu IsodaInstitute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.
Yoshihiro SakodaInstitute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.
Takasuke FukuharaDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0001-5471-8331

Funding

Hokkaido University (HU)Hokuto Foundation for BioscienceJapan Agency for Medical Research and Development (AMED) JP21fk0108617h0001Japan Agency for Medical Research and Development (AMED) JP22gm1610008h0001Kuribayashi Scholarship Academic FoundationMEXT | Japan Science and Technology Agency (JST) JPMJSP2119MEXT | Japan Society for the Promotion of Science (JSPS) 21H02736MEXT | Japan Society for the Promotion of Science (JSPS) JP23K20041Takeda Medical Research Foundation
6 · The paper itself

Abstract

Reverse genetics systems have played a central role in developing recombinant viruses for a wide spectrum of virus research. The circular polymerase extension reaction (CPER) method has been applied to studying positive-strand RNA viruses, allowing researchers to bypass molecular cloning of viral cDNA clones and thus leading to the rapid generation of recombinant viruses. However, thus far, the CPER protocol has only been established using cap-dependent RNA viruses. Here, we demonstrate that a modified version of the CPER method can be successfully applied to positive-strand RNA viruses that use cap-independent, internal ribosomal entry site (IRES)-mediated translation. As a proof-of-concept, we employed mammalian viruses with different types (classes I, II, and III) of IRES to optimize the CPER method. Using the hepatitis C virus (HCV, class III), we found that inclusion in the CPER assembly of an RNA polymerase I promoter and terminator, instead of those from polymerase II, allowed greater viral production. This approach was also successful in generating recombinant bovine viral diarrhea virus (class III) following transfection of MDBK/293T co-cultures to overcome low transfection efficiency. In addition, we successfully generated the recombinant viruses from clinical specimens. Our modified CPER could be used for producing hepatitis A virus (HAV, type I) as well as IMPORTANCE: The lack of versatility of reverse genetics systems remains a bottleneck in viral research. Especially when (re-)emerging viruses reach pandemic levels, rapid characterization and establishment of effective countermeasures using recombinant viruses are beneficial in disease control. Indeed, numerous studies have attempted to establish and improve the methods. The circular polymerase extension reaction (CPER) method has overcome major obstacles in generating recombinant viruses. However, this method has not yet been examined for positive-strand RNA viruses that use cap-independent, internal ribosome entry site-mediated translation. Here, we engineered a suitable gene cassette to expand the CPER method for all positive-strand RNA viruses. Furthermore, we overcame the difficulty of generating recombinant viruses because of low transfection efficiency. Using this modified method, we also successfully generated reporter viruses and recombinant viruses from a field sample without virus isolation. Taking these findings together, our adapted methodology is an innovative technology that could help advance virologic research.

Indexed as

Hepatitis CProtein BiosynthesisReverse GeneticsAnimalsInternal Ribosome Entry SitesMammalsPositive-Strand RNA VirusesRNA, ViralInternal Ribosome Entry SitesRNA, Viralcap-independenceIRESreporter virusreverse geneticsRNA virus

Identifiers

PMID38353536
PMCPMC10949505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.